TBI-223 is a novel oxazolidinone with potentially reduced myelosuppression, compared to linezolid. TBI-223 may be considered an additional treatment against MRSA infections and potentially other Gram-positive bacteria in humans.
Machine-generated and unreviewed. Identity, structure and cross-references come straight from ChEBI's and CARD's own data; no curator has signed off on this record yet.
oxazolidinone antibioticARO:3000079
ARO:3000079| Molecular formula | C17H20FN3O5 |
|---|---|
| Charge | 0 |
| Average mass | 365.4 Da |
| Monoisotopic mass | 365.13869891 Da |
| Source | PubChem · retrieved 2026-08-29 |
| InChIKey | ZNBRXLSWXJKKLJ-LBPRGKRZSA-N |
COC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4(C3)COC4)F
InChI=1S/C17H20FN3O5/c1-24-15(22)19-5-12-6-21(16(23)26-12)11-2-3-14(13(18)4-11)20-7-17(8-20)9-25-10-17/h2-4,12H,5-10H2,1H3,(H,19,22)/t12-/m0/s1
| Source | Native ID | Label | Minted CURIE | Version |
|---|---|---|---|---|
| ARO | ARO:3007480 |
TBI-223 | antibioticmech:aro-67d13cef91 |
2026-08-30 |
Seeded from data/raw/ inventories (ARO)
Re-seeded from updated data/raw/ inventories
Re-seeded from updated data/raw/ inventories